MR finds contralateral breast cancer in elders
MRI detects breast cancer in the contralateral breast for postmenopausal women better than a clinical or mammographic examination, according to a Mayo Clinic study published in the March/April The Breast Journal.
MRI detects breast cancer in the contralateral breast for postmenopausal women better than a clinical or mammographic examination, according to a Mayo Clinic study published in the March/April The Breast Journal.
The researchers found 16 of 425 women, all postmenopausal, had breast cancer in the undiagnosed breast. Furthermore, patients 70 and older had a higher prevalence of cancer detected in the second breast than their younger counterparts. MRI found a cancer in seven of the 129 women 70 and older. Mammography and clinical examination did not detect cancer in any of the contralateral breasts.
“Elderly women in good health potentially benefit from earlier detection, and we believe that screening the undiagnosed breast with MRI should be considered in all postmenopausal women diagnosed with a breast cancer,” said lead investigator Dr. Johnny Ray Bernard Jr., a radiation oncologist at the Mayo Clinic in Jacksonville, FL.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
